Advancing complement inhibition for the treatment of malarial anemia: a translational roadmap
Year: 2026
Type: article
Abstract: Severe anemia is responsible for hundreds of thousands of deaths in children with malaria. For every Plasmodium -infected erythrocyte that is lysed, considerably more than 10 uninfected erythrocytes are cleared by extravascular hemolysis, thus leading to anemia. Compelling evidence indicates that breakdown products released from infected erythrocytes in the bloodstream activate complement and promote “innocent bystander” deposition of C3 activation fragments on the uninfected erythrocytes, thereby sensitizing them for elimination. We propose a series of in vitro experiments with blood cultures of malaria parasites to test the hypothesis that use of inhibitors that block complement at the C3 activation step can preserve and protect uninfected erythrocytes from C3 deposition. Successful demonstration of in vitro protection will set the stage for clinical trials based on the limited and focused use of complement inhibitors to prevent severe anemia in malaria.
Source: Malaria Journal
Institutions: University of Virginia Health System, University of Virginia Medical Center, University of Virginia, University of Pennsylvania, National Centre of Scientific Research "Demokritos", Istituto per lo Studio e la Prevenzione Oncologica, Walter Reed Army Institute of Research, Azienda Ospedaliera S.Giuseppe Moscati, Universität Ulm, University of Iowa, Kenya Medical Research Institute
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
OpenAlex ID: W7204195025
FWCI:
Cites:
Cited by:
Related to:
